Suppr超能文献

1α,25-二羟维生素 D 与人参皂苷 Rh2 协同增强人前列腺癌细胞的抗癌作用。

1α,25-Dihydroxyvitamin D synergistically enhances anticancer effects of ginsenoside Rh2 in human prostate cancer cells.

机构信息

Vancouver Prostate Centre at Vancouver General Hospital, 2660 Oak Street, Vancouver, BC, V6H 3Z6, Canada; Therapeutics Initiative, Department of Anesthesiology, Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.

Department of Pharmaceutical Sciences, College of Pharmacy, Larkin University, 18301 N. Miami Avenue, Miami, FL, 33169, USA.

出版信息

J Steroid Biochem Mol Biol. 2021 May;209:105828. doi: 10.1016/j.jsbmb.2021.105828. Epub 2021 Jan 22.

Abstract

1α,25-dihydroxyvitamin D (1,25(OH)D, commonly known as calcitriol), the most active metabolite of vitamin D, and ginsenoside Rh2 can regulate cellular differentiation and proliferation proteins. The purpose of the present study was to assess the effect of 1,25(OH)D on the anticancer activities of Rh2 in human prostate cancer cells such as androgen-dependent LNCaP and androgen-independent C4-2 in vitro. The effects of treatment with 1,25(OH)D or Rh2, either alone or in combination, on prostate cancer cells were evaluated through tetrazolium-based cell viability assay, BrdU cell proliferation rate estimation assay, and Western blot protein expression analyses of nuclear receptors (androgen receptor and vitamin D receptors) and apoptotic proteins (Bcl-2, Bax, and Caspase 3). The Combination Indices (CI) and Dose Reduction Indices (DRI) of 1,25(OH)D and Rh2 were calculated to determine synergistic anticancer activity using Calcusyn software (Biosoft, Cambridge, UK). The cell viability assay data indicate that Rh2 treatment alone inhibited cell viability in a concentration-dependent manner and the addition of 10 nM 1,25(OH)D to Rh2 significantly enhanced its ability to reduce cell viability up to 80 % in both the cell lines. Similarly, addition of 10 nM 1,25(OH)D to Rh2 significantly lowered its IC values for cell proliferation from the range of 32-65 μM to 14-8 μM in LNCaP and C4-2 cells. In addition, protein expression analyses indicated that the combined treatment with Rh2 and 1,25(OH)D led to greater downregulation of androgen receptor expression compared to single agent exposure. Similarly, the presence of 1,25(OH)D synergistically increased the pro-apoptotic actions of Rh2 in both the cell lines. Overall, 1,25(OH)D augments the Rh2-mediated anticancer effects through stimulating apoptosis and reduced cell proliferation which suggests that synergism of this combination may lead to potential lower need of the active vitamin D and limited toxicity from it.

摘要

1α,25-二羟维生素 D(1,25(OH)D,俗称骨化三醇)是维生素 D 的最活跃代谢物,可调节细胞分化和增殖蛋白。本研究旨在评估 1,25(OH)D 对雄激素依赖性 LNCaP 和雄激素非依赖性 C4-2 等体外人前列腺癌细胞中 Rh2 的抗癌活性的影响。通过四唑基细胞活力测定、BrdU 细胞增殖率估计测定以及核受体(雄激素受体和维生素 D 受体)和凋亡蛋白(Bcl-2、Bax 和 Caspase 3)的 Western blot 蛋白表达分析,评估单独或联合使用 1,25(OH)D 或 Rh2 对前列腺癌细胞的影响。使用 Calcusyn 软件(英国剑桥 Biosoft)计算 1,25(OH)D 和 Rh2 的组合指数(CI)和剂量减少指数(DRI),以确定协同抗癌活性。细胞活力测定数据表明,Rh2 处理单独以浓度依赖方式抑制细胞活力,并且将 10 nM 1,25(OH)D 添加到 Rh2 中可显著增强其降低细胞活力的能力,在两种细胞系中高达 80%。同样,将 10 nM 1,25(OH)D 添加到 Rh2 中可将其对细胞增殖的 IC 值从 LNCaP 和 C4-2 细胞的 32-65 μM 范围降低至 14-8 μM。此外,蛋白表达分析表明,与单一药物暴露相比,联合使用 Rh2 和 1,25(OH)D 导致雄激素受体表达的下调更大。同样,1,25(OH)D 的存在协同增强了 Rh2 在两种细胞系中的促凋亡作用。总体而言,1,25(OH)D 通过刺激凋亡和减少细胞增殖来增强 Rh2 介导的抗癌作用,这表明这种组合的协同作用可能导致对活性维生素 D 的需求降低,同时限制其毒性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验